ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Report
Delayed Nasdaq  -  04:00 2022-06-30 pm EDT
11.40 USD   -2.40%
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 2500 Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 3000E Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 3000 Growth Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Allogene Therapeutics Named 2022 Bay Area 'Best Place to Work' by San Francisco Business Times and Silicon Valley Business Journal

05/10/2022 | 09:20am EDT

SOUTH SAN FRANCISCO, Calif. - Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer, announced that the San Francisco Business Times and the Silicon Valley Business Journal ranked Allogene as the highest rated biotechnology company - and 12th company overall - on the 2022 Best Places to Work in the Bay Area list in the large company category (200-499 employees).

Winning organizations were selected from over 400 competing Bay Area companies that have created exceptional workplaces that their employees value highly. Results were based on a survey of employees measuring engagement and other workplace factors including: communication and resources, individual needs, manager effectiveness, personal engagement, team dynamics and trust in leadership.

'Our people are the heart and soul of Allogene, and this recognition is a testament to the One Allogene company culture we've worked so hard to build,' said David Chang, M.D., Ph.D., President, CEO and Co-Founder of Allogene. 'This award is especially meaningful because it stems from honest, voluntary employee feedback and truly illustrates our collective mission of developing life-saving products for patients with cancer.'

On May 1, 2022, Allogene celebrated its four-year anniversary with its more than 300 employees who together continue to nurture its One Allogene culture. The Company, which is actively recruiting new employees, was also recently named a 2022 Best Place to Work by BioSpace. For more information, visit the Allogene Careers web site.

About Allogene Therapeutics

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of 'off-the-shelf' CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'proposed,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to recruit, develop and retain employees; the ability to develop allogeneic CAR T products for cancer and the potential benefits of AlloCAR T. Various factors may cause differences between Allogene's expectations and actual results as discussed in greater detail in Allogene's filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-Q for the quarter ended March 31, 2022. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact:

Allogene Media/Investor

Christine Cassiano

Chief Communications Officer

T: (714) 552-0326

E: Christine.Cassiano@allogene.com

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about ALLOGENE THERAPEUTICS, INC.
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 2500 Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 3000E Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 3000 Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell Small Cap Comp Growth In..
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 2000 Growth Index
CI
06/23INSIDER SELL : Allogene Therapeutics
MT
06/17ALLOGENE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders, Financi..
AQ
06/13TRANSCRIPT : Allogene Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Heal..
CI
06/08Allogene Therapeutics Shares Rise 9% After FDA Approves Trial for Lymphoma
DJ
06/08Allogene's Potential Cancer Treatment Gets FDA's Regenerative Medicine Advanced Therapy..
MT
More news
Analyst Recommendations on ALLOGENE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 0,12 M - -
Net income 2022 -367 M - -
Net cash 2022 326 M - -
P/E ratio 2022 -4,42x
Yield 2022 -
Capitalization 1 637 M 1 637 M -
EV / Sales 2022 10 784x
EV / Sales 2023 246x
Nbr of Employees 334
Free-Float 55,8%
Chart ALLOGENE THERAPEUTICS, INC.
Duration : Period :
Allogene Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLOGENE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 11,40 $
Average target price 25,71 $
Spread / Average Target 125%
EPS Revisions
Managers and Directors
David D. Chang President, Chief Executive Officer & Director
Eric Schmidt Chief Financial Officer
Arie S. Belldegrun Executive Chairman
Alison Moore Chief Technical Officer
Barbra Sasu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ALLOGENE THERAPEUTICS, INC.-21.72%1 677
GILEAD SCIENCES, INC.-13.95%78 370
VERTEX PHARMACEUTICALS27.66%71 701
REGENERON PHARMACEUTICALS, INC.-5.37%64 391
WUXI APPTEC CO., LTD.-12.30%44 027
BIONTECH SE-44.93%34 504